Articles related to HEART FAILURE (HF)

Semaglutide treatment led to more frequent improvement and less frequent deterioration in NYHA functional class compared to placebo in patients with obesity-related HFpEF over 52 weeks.

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

In managing acute decompensated heart failure, optimizing loop diuretic therapy is pivotal; initial aggressive dosing tailored to urinary outputs can significantly improve patient outcomes.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.

Experience an in-depth exploration of heart failure management in Mont-Tremblant, Canada, where you’ll delve into the latest diagnostic and therapeutic advancements, gaining insights that are crucial for enhancing patient outcomes in your practice.

Marlex Pharmaceuticals has initiated a critical recall of specific lots of Digoxin Tablets due to a labeling error. Physicians are urged to exercise extreme caution and verify their inventory to prevent adverse patient outcomes.